Publications
1. Rogers KA, Huang Y, Ruppert AS, Abruzzo LV, Andersen BL, Awan FT, Bhat SA, Dean A, Lucas M, Banks C, Grantier C, Heerema NA, Lozanski G, Maddocks KJ, Valentine TR, Weiss DM, Jones JA, Woyach JA, Byrd JC. Phase II Study of Combination Obinutuzumab, Ibrutinib and Venetoclax in Treatment-Naive and Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol. 2020 Nov 1; 38(31):3626-3637. PMID: 32795224. PMCID: PMC7605394.
2. Lucas F*, Rogers KA*, Harrington BK*, Pan A, Yu L, Breitbach J, Bundschuh R, Goettl VM, Hing ZA, Kanga P, Mantel R, Sampath D, Smith LL, Wasmuth R, White DK, Yan P, Byrd JC, Lapalombella R, Woyach JA. Emu-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma. Clin Cancer Res. 2019 Oct 15; 25(20):6260-6273. PMID: 31296529. PMCID: PMC6801062. *Denotes co-first authors.
3. Rogers KA, Huang Y, Ruppert AS, Awan FT, Heerema NA, Hoffman C, Lozanski G, Maddocks KJ, Moran ME, Reid MA, Lucas M, Woyach JA, Whitlow WT, Jones JA, Byrd JC. Phase 1B Study of Obinutuzumab, Ibrutinib and Venetoclax in Relapsed and Refractory Chronic Lymphocytic Leukemia. Blood. 2018 Oct 11; 132(15):1568-1572. PMID: 30592587. PMCID: PMC6182267.
4. Rogers KA, Ruppert AS, Bingman A, Andritsos LA, Awan FT, Blum KA, Flynn JM, Jaglowski SM, Lozanski G, Maddocks KJ, Byrd JC, Woyach JA, Jones JA. Incidence and Description of Autoimmune Cytopenias During Treatment With Ibrutinib for Chronic Lymphocytic Leukemia. Leukemia. 2016 Feb; 30(2):346-50. PMID: 26442611. NIHMSID: MIHMS806060. PCMID: PMC4986508.
Meeting Abstracts
1. Rogers KA, Flinn IW, McGarry C, Gou LC, Hassounah N, Woo J, Byrd JC. Phase 1B Study of Ianalumab (VAY736) and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy. Blood. 2020; 136(Supplement 1):13-14. American Society of Hematology Annual Meeting, Virtual. December 2020.
2. Rogers KA, Boxer MA, Choi MY, Agajanian R, Arnold DM, Broome CM, Field JJ, Murakhovskaya I, Chow D, Numerof RP, Zheng H, Tong S, Kuter DJ. Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicenter, Open-Label Study. Blood. 2019; 134(Supplement_1):3518-3518. American Society of Hematology Annual Meeting, Orlando, FL. December 2019.
3. Rogers KA, Lehman AM, Cheney C, Goettl VM, Mantel R, Smith LL, Tran M, Johnson AJ, Byrd JC, Woyach JA. Inhibitors of Bruton's Tyrosine Kinase Reduce Anti-Red Blood Cell Response in a Murine Model of Autoimmune Hemolytic Anemia. Blood. 2016; 128(22):1259-1259. American Society of Hematology 58th Annual Meeting, San Diego, CA. December 2016.
4. Rogers KA, El-Gamal D, Bonnie HK, Zachary HA, Virginia GM, Rose M, Smith LL, Yu L, Johnson AJ, Byrd JC, Lapalombella R, Woyach JA. The Eµ-Myc/TCL1 Transgenic Mouse as a New Aggressive B-Cell Malignancy Model Suitable for Preclinical Therapeutics Testing. Blood. 2015; 126(23):2752-2752. American Society of Hematology 57th Annual Meeting, Orlando, FL. December 2015.
5. Rogers KA, Woyach JA, Andritsos LA, Awan F, Blum KA, Flynn JM, Jaglowski S, Lozanski G, Maddocks KJ, Byrd JC, Jones JA. Incidence of Autoimmune Cytopenias (AIC) in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) Patients (Pts) Treated With Ibrutinib. Blood. 2014; 124(21):1997-1997. American Society of Hematology 56th Annual Meeting, San Francisco, CA. December 2014.